Tuesday, 16 Jul 2019

You are here

Opioid Use in Osteoarthritis Varies by State

A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

Researchers set out to assess the level of opioid use in the year preceding a TJR and overall among Medicare beneficiaries with advanced osteoarthritis and if there were geographical variations in rates of treatment with long-term opioid therapy in osteoarthritis.  (Citation source: https://buff.ly/2FZ5atJ)

An observational cohort study of 358,121 osteoarthritis patients undergoing total joint replacement (TJR) examined long‐term opioids (≥ 90 days in the 360‐day period immediately preceding TJR) use.

Over the study years (2011 to 2014) the proportion of TJR patients using long-term opioids remained relatively stable (16.8% in 2011, 16.8% in 2012, 16.6% in 2013, and 16.3% in 2014).

They found that the unadjusted mean % of long‐term opioid users varied widely across states, ranging from 8.9% (Minnesota) to 26.4% (Alabama).

PCPs access was only modestly associated with rates of long‐term opioid use, while access to rheumatologists was not associated with long‐term opioid use.

Statewide variation in long‐term opioid use in osteoarthritis was not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

 

 

 

Add new comment

More Like This

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays. A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

Mortality from Falls in the Elderly

JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age. 

Knee Injuries Increases Osteoarthritis Risk

A systematic review of the medical literature shows anterior cruciate ligament (ACL), meniscus or combined ACL and meniscus injury significantly increases the risk of future knee osteoarthritis (OA).

The metanalysis comprised 53 studies and nearly 1 million participants, including 185,219 with ACL injury (mean age 28 years), 83,267 with meniscal injury (mean 38 years) and 725,362 with combined injury (mean 31 years).

Additive Effects of Insomnia and Depression on Osteoarthritis

A study of osteoarthritis patients, finds that pain is the primary driver for health care utilization, and that the presence of insomnia or depression augments health care use.

 A total of 2976 OA patients were followed for 3 years and assessed for pain (Graded Chronic Pain Scale), insomnia (Insomnia Severity Index), and depression (Patient Health Questionnaire‐8), and health care use (from electronic health records).